Importantly, our findings demonstrate that the patient-derived cancer cell lines initially used to define the SCLC-Y subtype actually represent SMARCA4-UT, NSCLC, or other SCLC mimics, and therefore are not representative models of “triple negative” or “inflamed” SCLC. The gene discussed is SMARCA4; the disease is cancer.